idelalisib and Lymphoma--B-Cell--Marginal-Zone

idelalisib has been researched along with Lymphoma--B-Cell--Marginal-Zone* in 1 studies

Other Studies

1 other study(ies) available for idelalisib and Lymphoma--B-Cell--Marginal-Zone

Article	Year
Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN, 2018, Volume: 16, Issue:3 Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell malignancy involving the spleen and bone marrow. Various cytogenetic abnormalities with prognostic value have been identified in SMZL. Complexity of karyotype, 14q aberrations, and Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Diagnostic Imaging; Female; Humans; Immunophenotyping; Lymphoma, B-Cell, Marginal Zone; Neoplasm Staging; Purines; Quinazolinones; Rituximab; Splenic Neoplasms; Treatment Outcome	2018

Article

Year

Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.

Journal of the National Comprehensive Cancer Network : JNCCN, 2018, Volume: 16, Issue:3

Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell malignancy involving the spleen and bone marrow. Various cytogenetic abnormalities with prognostic value have been identified in SMZL. Complexity of karyotype, 14q aberrations, and

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Diagnostic Imaging; Female; Humans; Immunophenotyping; Lymphoma, B-Cell, Marginal Zone; Neoplasm Staging; Purines; Quinazolinones; Rituximab; Splenic Neoplasms; Treatment Outcome

2018